Lee HF, Chan YH, Li PR, et al. - In order to generate data on clinical results for oral anticoagulants and antiplatelet treatment (APT) in atrial fibrillation (AF) patients encountering critical limb ischemia (CLI), researchers performed this nationwide retrospective cohort analysis. Using the Taiwan National Health Insurance Research Database, they selected 1,223 AF patients with CLI receiving DOACs, warfarin, or APT. In AF patients with concomitant CLI, a significantly lower risk of composite net-clinical-benefit outcome (ischemic stroke/systemic embolism, acute myocardial infarction, all major adverse limb events, plus all major bleeding events) was observed in relation to DOAC vs either warfarin or APT. In high subgroups including age > 75 years old, presence of diabetes mellitus, or chronic kidney disease, the persisted decreased risk of net-clinical-benefit outcome for DOAC vs warfarin or APT was reported.